Mirtazapine
30 mg · Tablet, Film Coated
- Prescription only
- Active substance
- Mirtazapine
- Made by
- Apotex Corp.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
This information is not included in the verified source. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Mirtazapine). It describes the substance, not this exact product.
The mechanism of action of mirtazapine for the treatment of major depressive disorder, is unclear.
However, its efficacy could be mediated through its activity as an antagonist at central presynaptic α 2 -adrenergic inhibitory autoreceptors and heteroreceptors and enhancing central noradrenergic and serotonergic activity.
Mirtazapine is extensively metabolized after oral administration.
Mirtazapine and its metabolites are eliminated predominantly (75%) via urine with 15% in feces.
Food Effect The presence of food in the stomach has a minimal effect on both the rate and extent of absorption.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-28
Safety of the active substance
From the US prescribing label for the same active substance (Mirtazapine). It describes the substance, not this exact product.
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies.
- Mirtazapine tablets are contraindicated in patients: Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.3), Drug Interactions (7) ].
- With a known hypersensitivity to mirtazapine or to any of the excipients in mirtazapine tablets.
- Severe skin reactions, including Stevens-Johnson syndrome, bullous dermatitis, erythema multiforme and toxic epidermal necrolysis have been reported following the use of mirtazapine tablets [see Adverse Reactions 6.2 ].
- Concomitant use of monoamine oxidase inhibitors (MAOIs) or use within 14 days of stopping MAOIs.
The most common reactions leading to discontinuation (≥1% and at a rate at least twice that of placebo) are included in Table 2.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
FranceNo exact match for this strength and form
Canada14 matching products
Details
| Made by | Apotex Corp. |
|---|---|
| Active substance | Mirtazapine |
| Strength | 30 mg |
| Form | Tablet, Film Coated |
| Route | Oral |
| Packs | 30 TABLET, FILM COATED in 1 BOTTLE · 100 TABLET, FILM COATED in 1 BOTTLE |
| NDC | 60505-0248 |
Source: NDC Directory · 2026-09-13 · not reviewed by a clinician
Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).
Other strengths and forms
107 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- Tablet, Film Coated84 products
30 mg24
30 mg · 24 companies
- A-S Medication Solutions
- American Health Packaging
- Aphena Pharma Solutions - Tennessee, LLC
- Apotex Corp. · this page
- Aurobindo Pharma Limited
- Aurolife Pharma LLC
- AvKARE
- Bryant Ranch Prepack
- Tablet, Orally Disintegrating14 products
- Tablet9 products
7.5 mg2
7.5 mg · 2 companies
15 mg2
15 mg · 2 companies
- 45 mg
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.